Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Reducing a-Synuclein in Human CSF; An Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1341, an a-Synuclein-specific antibody, in Healthy Volunteers and Parkinson’s Disease Patients

              Author:Shering, Craig   Pomfret, Michael   kubiak, Robert   Pouliquen, Isabelle   Yin, Wei   Simen, Arthur   Ratti, Elena   Perkinton, Michael   Tan, Keith   Chessell, Iain   Ostenfeld, Thor   

              Session Name:P1: Movement Disorders: Clinical Trials in Parkinson's Disease 1  

              Topic:Movement Disorders  

              Program Number:P1.007  

              Author Institution:Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, US, Boston, MA  Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom  Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, US, Gaithersburg, MD  Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK, Cambridge, United Kingdom  Takeda Development Center Americas Inc., Lexington, MA, US, Lexington, MA